Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Aug '25 Aug 14, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	151	174	88	28	29	38	Upgrade
Market Cap Growth	97.16%	97.16%	219.36%	-4.32%	-24.65%	-66.14%	Upgrade
Enterprise Value	189	209	118	44	34	23	Upgrade
Last Close Price	7.56	8.95	4.95	1.55	1.62	2.15	Upgrade
PE Ratio	10.47	11.72	-	-	-	-	Upgrade
Forward PE	-	10.63	-	7.84	-	-	Upgrade
PS Ratio	3.13	3.61	10.48	4.59	4.84	6.74	Upgrade
PB Ratio	110.32	127.32	-3.17	-1.99	8.98	2.06	Upgrade
P/TBV Ratio	110.32	127.32	-	-	8.98	2.06	Upgrade
EV/Sales Ratio	3.92	4.34	13.95	7.26	5.77	4.13	Upgrade
EV/EBITDA Ratio	7.64	8.52	-	-	-	-	Upgrade
EV/EBIT Ratio	7.70	8.53	-	-	-	-	Upgrade
Debt / Equity Ratio	34.62	34.62	-1.62	-3.25	13.87	1.53	Upgrade
Debt / EBITDA Ratio	1.91	1.91	-	-	-	-	Upgrade
Asset Turnover	1.15	1.15	0.29	0.14	0.11	0.09	Upgrade
Quick Ratio	2.42	2.42	0.62	5.50	10.58	5.50	Upgrade
Current Ratio	2.60	2.60	0.68	5.65	10.79	5.50	Upgrade
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%	Upgrade
Return on Assets (ROA)	36.44%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%	Upgrade
Return on Capital (ROIC)	46.45%	46.45%	-28.99%	-21.37%	-17.21%	-23.21%	Upgrade
Return on Capital Employed (ROCE)	64.80%	64.80%	-	-	-	-	Upgrade
Earnings Yield	9.85%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%	Upgrade
FCF Yield	-10.96%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%	Upgrade
Buyback Yield / Dilution	-15.30%	-15.30%	-	-	-	-	Upgrade

Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.